相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A phase II study evaluated tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type colorectal cancer as part of the MOUNTAINEER trial. - The combination therapy demonstrated clinical activity in this heavily pretreated patient population with limited treatment options. - The study represents a significant advance in targeting HER2-positive colorectal cancer, a rare but clinically important subset representing approximately 2-3% of all colorectal cancers. - Results support further investigation of HER2-targeted dual blockade strategies in this challenging patient population.
- New data from a 2,854-patient registry study shows Blue Light Cystoscopy detected additional malignant lesions in 7% of cases that were missed by standard white light examination. - The enhanced detection capabilities led to cancer upstaging in 9.3% of cases, potentially altering treatment decisions regarding intravesical therapy and surgical interventions. - The study revealed 335 additional tumors detected only by Blue Light Cystoscopy, with 43% being carcinoma in-situ and 40% representing high-grade tumors.
- A new multicenter study across three major medical institutions demonstrates Daxor's Blood Volume Analysis (BVA) provides superior accuracy over conventional pressure-based measurements in heart failure patients. - Research published in the Journal of Cardiac Failure reveals BVA's unique ability to detect anemia and identify sex-specific volume differences, enabling more personalized treatment approaches. - The study, analyzing 255 heart failure patients, confirms BVA's 98% accuracy in volume assessment, highlighting its potential to improve patient outcomes through precise diagnosis.
- The COORDINATE-Diabetes trial significantly improved the adoption of essential therapies, including high-intensity statins and SGLT2 inhibitors, in cardiology clinics for T2D patients with ASCVD. - The trial addressed a critical gap where initially only 3-4% of patients were receiving all recommended therapies, leading to significant improvements in treatment adherence. - Recent advancements highlight the broader cardiovascular and kidney-related benefits of therapies like GLP-1 receptor agonists and SGLT2 inhibitors, beyond glucose and weight management.
- The NIH's RECOVER Initiative has launched multiple clinical trials targeting key long COVID symptoms including sleep disturbances, exercise intolerance, post-exertional malaise, and autonomic nervous system dysfunction. - Approximately 1,660 participants will be enrolled across 50 study sites to test treatments for sleep issues, while 380 participants will join trials evaluating therapies for postural orthostatic tachycardia syndrome (POTS). - The trials were developed with significant input from patients and community representatives, with diversity among participants being a high priority for researchers.
